BioNTech SE Expense From Cashsettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
BioNTech SE (BNTX) reported Expense From Cashsettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of EUR 17.30 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2026-03-10
| Period end | Expense From Cashsettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month | Expense From Cashsettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month as first filed |
|---|---|---|
| 2025-12-31 | 17.30M EUR 20-F · filed 2026-03-10 | |
| 2024-12-31 | 26.00M EUR 20-F · filed 2026-03-10 | 15.90M EUR 20-F · filed 2025-03-10 |
| 2023-12-31 | 7.30M EUR 20-F · filed 2026-03-10 | |
| 2022-12-31 | 61.50M EUR 20-F · filed 2025-03-10 | |
| 2021-12-31 | 32.70M EUR 20-F · filed 2024-03-20 | |
| 2020-12-31 | 700.00K EUR 20-F · filed 2023-03-27 | |
| 2019-12-31 | 0.00 EUR 20-F/A · filed 2022-10-26 |